Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01822509
Title Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

multiple myeloma

hematologic cancer

Hodgkin's lymphoma

chronic myeloid leukemia

acute leukemia

myelodysplastic syndrome

non-Hodgkin lymphoma

myelodysplastic/myeloproliferative neoplasm

chronic lymphocytic leukemia

Therapies

Ipilimumab + Nivolumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
UC San Diego Moores Cancer Center La Jolla California 92093 United States Details
City of Hope South Pasadena South Pasadena California 91030 United States Details
Colorado Blood Cancer Institute Denver Colorado 80218 United States Details
Moffitt Cancer Center-International Plaza Tampa Florida 33607 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Northside Hospital Atlanta Georgia 30342 United States Details
Eastern Maine Medical Center Bangor Maine 04401 United States Details
Lafayette Family Cancer Center-EMMC Brewer Maine 04412 United States Details
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Massachusetts General Hospital Charlestown Massachusetts 02129 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field